Tretinoin, also known as all-trans retinoic acid, is a medication used for the treatment of acne and acute promyelocytic leukemia. For acne, it is applied to the skin as a cream, gel or ointment. Technically, tretinoin is a carboxylic acid derivative of vitamin A that binds retinoic acid receptors in keratinocytes and myeloid cells to modulate gene transcription, increase epidermal cell turnover, normalize desquamation, and reduce follicular occlusion and inflammation; in acute promyelocytic leukemia it targets the PML-RARalpha oncoprotein to induce differentiation of promyelocytes. Topical formulations range commonly from 0.01 to 0.1 percent and differ by vehicle and release profile, which affects penetration and irritation potential. Tretinoin is chemically sensitive to light, heat and oxidation and undergoes geometric isomerization to 9-cis and 13-cis forms, so formulation and packaging are designed to minimize degradation and maintain potency. Systemic pharmacokinetics for oral all-trans retinoic acid include rapid absorption, extensive protein binding and hepatic metabolism, and dosing and monitoring differ substantially between dermatologic topical use and systemic leukemia therapy.
Parent: Tretinoin
Parent: Tretinoin
Parent: Tretinoin
Parent: Tretinoin
Related substances and impurities for tretinoin include geometric isomers such as 13-cis retinoic acid (isotretinoin) and 9-cis retinoic acid, oxidized species like 4-oxo-tretinoin and other carbonyl products, epoxide or polymeric degradation products, residual solvents and trace synthetic byproducts; pharmacopoeial and regulatory specifications typically control these by name or by total related-substance limits. Typical quality control criteria applied by manufacturers and monographs vary by dosage form and regulatory region, but individual related compounds are commonly limited to the low tenths of a percent range and total impurities to low single-digit percent levels; for example, acceptance criteria may be in the order of <= 0.1 to 0.5 percent for specific identified impurities and <= 1.0 to 3.0 percent for total impurities depending on the monograph, intended use and ICH Q3 guidance. Analytical methods used include HPLC with diode array detection, LC-MS and stability-indicating assays to quantify isomerization and oxidative degradation and to ensure batches meet release criteria.
Tretinoin accelerates epidermal cell turnover, reduces cohesion of follicular epithelial cells to prevent comedone formation, promotes exfoliation, and has anti-inflammatory effects; clinically this results in reduced acne lesions, improved texture and, over time, modulation of fine photodamage through collagen remodeling.
Many patients use topical tretinoin daily, often once nightly, but initiation typically begins with less frequent application or lower concentration to assess tolerance; frequency should be individualized based on skin response and guidance from a prescriber to manage irritation and dryness.
Tretinoin is contraindicated in people with hypersensitivity to retinoids and should not be used during pregnancy or by those planning pregnancy because of teratogenic risk when systemic exposure occurs; use with caution in individuals with severely irritated or sunburned skin and consult a clinician for concurrent skin conditions and medications that increase photosensitivity.
In many countries topical tretinoin is available only by prescription because of its potency, irritation potential and contraindications, while concentrations and regulatory status vary by region, so local medical guidance and prescription requirements should be checked.
